Blueprint Medicines is experiencing growth with its core revenue driver, AYVAKIT, which is gaining traction in systemic mastocytosis and gastrointestinal stromal tumors. The drug's expansion into Germany and potential for further indications support the company's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.